Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
Lantheus Holdings, Inc. reported its financial results for Q1 2026, highlighting strong performances from its products PYLARIFY, Neuraceq, and DEFINITY. The company secured FDA approval for PYLARIFY TruVu and achieved tentative approval for PNT2003, with plans to expand its Alzheimer’s imaging portfolio and maintain its leadership in PSMA PET. The company remains focused on disciplined capital deployment and growth acceleration starting in 2027.
Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026 GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025 Adjusted fully diluted earnings per share of $1.46, compared to $1.53 in the first quarter of 2025 FDA approves